Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced that its Vice President, Finance and Chief Financial Officer, Brent Larson, will present on Tuesday, May 18, 2010 at 11:30AM BST, in the Spencer Suite, during the Rodman & Renshaw Annual Global Investment Conference to be held at the Grosvenor House Hotel in London, UK. Mr. Larson’s presentation will provide an overview of the Company’s technology and business strategy.

Interested parties can access a live, or an archived internet broadcast of the presentation at:

The presentation will be archived for 30 days.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe ® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek ® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

Copyright Business Wire 2010